Eukleidiline

Eukleidiline is a synthetic oligomer that has attracted interest for its applications in biomedical imaging and drug delivery. First synthesized in 2019 by a research group at the University of Berlin, the compound was named after the ancient Greek mathematician Euclid in recognition of its unique symmetry properties that resemble planar Euclidean tiling. Chemically, eukleidiline is a low‑molecular‑weight poly(ethylene imine) derivative that incorporates a cyclic ether motif. Its molecular formula is C15H28N4O3 and it possesses a zwitterionic surface that enables strong, reversible binding to nucleic acids.

Early studies demonstrated that eukleidiline can complex with short DNA strands and ribosomal RNA, providing a non‑viral delivery platform for gene‑silencing agents. In addition, the compound has been used to enhance the contrast of magnetic resonance imaging, owing to its ability to chelate gadolinium ions without releasing them in physiological conditions. Toxicological assessments in vitro showed minimal cytotoxicity at concentrations up to 50 µg/mL, whereas in vivo studies in rodents indicated a transient, dose‑dependent reduction in liver enzyme levels. No long‑term adverse effects have been reported, and the compound is currently under investigation in Phase I clinical trials for the treatment of liver fibrosis.

Although eukleidiline shows promise, its environmental persistence remains unclear, and further research is needed to evaluate its biodegradability. The compound is not yet approved for clinical use outside of investigational studies, and its commercial availability is restricted to research laboratories that have obtained the necessary regulatory permissions.